MOUNTAIN VIEW, Calif., Jan. 5 /PRNewswire-FirstCall/ -- VIVUS, Inc. today announced that Leland Wilson, chief executive officer, will present an overview of the company at the 28th Annual JP Morgan Healthcare Conference.
About VIVUS
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company’s lead product in clinical development, Qnexa(R), has completed phase 3 clinical trials for the treatment of obesity and an NDA was submitted to the FDA in December 2009. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor for the treatment of erectile dysfunction, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.
CONTACT: Timothy E. Morris, Chief Financial Officer, VIVUS, Inc.,
+1-650-934-5200; or Investor Relations: The Trout Group, Brian Korb,
+1-646-378-2923; or Media Relations: Dan Budwick, Pure Communications,
Inc., +1-973-271-6085
Web site: http://www.vivus.com/
